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ABSTRACT 
The recent synthesis of selective agonists and antagonist 
of the neurohypophyseal peptides has opened up a new avenue 
for investigating their complex pharmacologic effects. 
Past investigators of the ocular effects of vasopressin 
have noted an ocular hypertensive effect in ethanol-treated 
rabbits with physiologic doses and a hypotensive effect 
associated with vasoconstriction and miosis with pharmacologic 
doses. 
P . . 
This paper attemts to characterize receptor mediation 
A. 
of effects of the neurohypophyseal peptides on the pupil 
and intraocular pressure of the rabbit through an approach 
which combines the use of synthetic analogs with an in vitro 
pupillometric system. The isolated rabbit iris demonstrated 
a constriction in response to neurohypophyseal peptides that 
best correlated with dose expressed as units of pressor 
activity and that was inhibited by d(CH^)^Tyr(Me)AVP, a 
specific vasopressor antagonist. Preliminary experiments 
indicate that the pupillary effect is exerted directly on 
the iris sphincter muscle, and is not mediated through 
prostaglandins or endogenous sensory neurotransmitters. 
Neurohypophyseal peptides were also administered by 
intravitreal injection in the living rabbit. The resulting 
miosis also correlated best with pressor activity. DDAVP, 
a synthetic analog with a much higher ratio of antidiuretic 
to pressor activity than vasopressin, had no significant 
effect on intraocular pressure in pharmacologic doses. 
Digitized by the Internet Archive 
in 2017 with funding from 
The National Endowment for the Humanities and the Arcadia Fund 
https://archive.org/details/effectofneurohypOOhoro 
It is tentatively concluded that vasopressin exerts 
a direct pressor-receptor mediated contractile effect on the 
sphincter muscle of the rabbit iris, and that its property 
of lowering intraocular pressure in pharmacologic doses 
is not mediated by an antidiuretic-1ike receptor in the 
rabbit eye. 
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INTRODUCTION 
The presence of diurnal variation in intraocular 
pressure and pupil diameter and the frequently noted 
association of endocrinological derangements with intra¬ 
ocular pressure abnormalities has led many investigators 
to search for an endogenous hormonal modulator of these 
ocular functions. The products of the neurohypophysis 
were early targets of this search. In the past, however, 
one was limited to relatively crude preparations of pos¬ 
terior pituitary extracts, which often led to variable and 
contradictory results. Today the investigator has at his 
disposal not only highly purified and synthetic hormone 
preparations but also a cornucopia of synthetic analogs 
with selective properties that enable one to sort out the 
complex activities of the native hormone. 
This paper links the old with the new. Certain 
ocular effects of neurohypophyseal peptides which have 
been studied for years are brought up to date in the light 
of current understanding of neurohypophyseal physiology 
and peptide chemistry. Then, in turn, recent findings 
are incorporated in a discussion of the phylogeny of cer¬ 
tain aspects of the vertebrate visual apparatus. 
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REVIEW OF THE LITERATURE 
The Neurohypophyseal Peptides - General Aspects 
The neurohypophysis of all vertebrate species studied 
to date contains one or more structural analogs of the mamma¬ 
lian hormones, vasopressin and oxytocin. Thus, the neuro¬ 
hypophyseal hormones constitute a phylogenetically old group 
1 2 
of neuropeptides. ’ (See figure 1) Vasotocin (AVT) is 
currently thought to have been the evolutionary precursor 
of all other neurohypophyseal peptides and has been found 
in the neurohypophysis of all vertebrates, except mammals. 
Lower vertebrates usually have, in addition to AVT, one 
other closely related oxytocin-like peptide. Mammalian 
neurohypophyses, on the other hand, contain oxytocin (OT) 
and arginine-vasopression (AVP) -- except for order Suina, 
in which lysine-vasopressin (LVP) is substituted for AVP. 
Both AVP and OT differ from AVT by only one amino acid 
residue; AVP is Phe^-AVT while OT is Leu^-AVT. 
In 1954 AVP and OT became the first peptide hormones 
to be sequenced and synthesized; the other neurohypophyseal 
3 
peptides have since followed suit. The naturally occurring 
peptides are endowed with a complex set of potent pharma¬ 
cologic activities in varying relative proportions; for¬ 
tunately a number of structure-activity relationships have 
been elucidated through the use of synthetic analogs. 
(Table 1) 
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From this approach, for example, it has been learned that 
the hexapeptide ring, which forms the structural backbone 
3 
of the molecule, is essential to biological activity. 
Spectroscopic methods have revealed very few differences 
among the naturally occurring hormones with respect to this 
backbone; vasopressins, for example, tend to display only 
a slightly greater structural rigidity than do oxytocin-like 
4 
peptides. However, the amino acid residues at positions 
3,4 and 8 are quite variable and the external orientation 
of their side chains free them to interact with specific 
receptor recognition sites. Amino acid substitutions at 
these positions, along with a few other minor modifications, 
have led to a host of synthetic analogs with pharmacologic 
properties much more specific than those of the natural 
peptides. For example, DDAVP (1-deamino, 8-D-arginine- 
vasopressin) has a much higher ratio of antidiuretic to 
pressor activity than does AVP and is currently the treat¬ 
ment of choice in diabetes insipidus because of its greater 
3 6 potency and therapeutic index. ’ Recently, potent and 
selective antagonists to the pressor effect have been syn¬ 
thesized; unfortunately, however, a good antagonist to 
the antidiuretic activity is still awaited. (This topic 
has been reviewed by Berde and Boissonnas/ and Manning 
et al.^) 
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Neurohypophyseal Peptides--General Physiologic Considerations 
In mammals, the neurohypophyseal peptides are synthe¬ 
sized by the magnocellular neurons located primarily in the 
supraoptic (SON) and paraventricular (PVN) hypothalamic 
9 
nuclei. From the neuronal cell bodies the hormones, in 
association with their respective carrier proteins or "neuro- 
physins," are transported axonally within secretory vesicles 
to the nerve endings in the posterior lobe of the pituitary. 
Hormones are released by a calcium-dependent exocytotic 
process triggered by depolarization of the nerve ending.^ 
Once in the bloodstream the hormones have a rather short 
half-life--about ten minutes for AVP and one to several 
minutes for OT--as they are rapidly degraded by plasma and 
tissue aminopeptidases or are removed by glomerular filtra- 
3,11 
tion, 
Only two well documented physiologically important 
roles have been found for the neurohypophyseal peptides-- 
the antidiuretic (ADH) action of AVT and AVP and the media¬ 
tion of the milk let-down reflex by OP. 
The ADH activity appears to be a result of an adenyl¬ 
ate cyclase-mediated increase in epithelial permeability 
12 13 
to water. ’ In land vertebrates the targets for the ADH 
effect are the collecting tubules in the kidney; in addi¬ 
tion the skin and bladder of amphibians respond to ADH. 
Release of the hormone occurs in response to volume deple- 
■ 
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tion or a rise in plasma osmolarity beyond an endogenously 
predetermined level. Furthermore a variety of drugs (es- 
14 pecially anesthesia), hypoxia , noxious stimuli, and intra- 
15 
ventricularly administered angiotensin have been shown to 
stimulate release. Failure to secrete sufficient ADH re¬ 
sults in inability to maintain a concentrated urine, a con¬ 
dition known in man as diabetes insipidus. 
Oxytocin has been shown to be essential for lactation. 
Unlike the epithelial action of ADH, oxytocin’s contractile 
effect on the myoepithelial cells lining mammary gland ducts 
does not appear to be mediated by adenylate cyclase, al- 
16 
though guanylate cyclase may be involved. Oxytocin also 
has a potent contractile effect on the myometrium, especial¬ 
ly in the gravid uterus, that is probably mediated by pros¬ 
taglandins. Oxytocin may not play an essential role ih 
parturition, since successful labor can occur in its com¬ 
plete absence, but it almost certainly plays a facilitative 
i 11 role. 
Both AVP and AVT have potent cardiovascular effects 
from which the name "vasopressin" was derived. The pressor 
response arises from a generalized vasoconstriction caused 
by a direct calcium mediated action on vascular smooth 
17 
muscle. This action has generally been thought to play 
no important physiologic role since plasma levels of vaso¬ 
pressin at which antidiuresis is maximally stimulated 
-12 -11 (10 to 10 M) produce no pressor response. However, 
. 
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this concept is being challenged because of the following 
findings: hemorrhage and volume depletion can stimulate 
release of AVP to the point where plasma levels are suffi¬ 
cient to produce a pressor response; during inhibition of 
baroreceptor reflexes by anesthesia, pressor responses can 
be demonstrated at even lower concentrations of AVP than 
12 previously thought; in vitro studies have shown that the 
post-capillary venules are the most sensitive component of 
the vascular system to vasopressin, suggesting that AVP 
might have an important microcirculatory effect that would 
not be adequately demonstrated by measurements of arterial 
blood pressure."^ Some investigators have even argued that 
vasopressin is an etiologic factor in essential hyperten- 
12 18 
sion. ’ In summary then, an important physiological 
role for AVP in circulatory homeostasis, especially in low 
flow states, cannot be ruled out. On the other hand, smooth 
muscle effects of vasopressin, such as on intestinal, uter¬ 
ine and bronchial smooth muscle, require high pharmacologic 
concentrations and are probably of no physiologic impor- 
19 
tance. 
The neurohypophyseal hormones have also been con¬ 
sistently shown to cause hyperglycemia in a wide range of 
vertebrate species. Pharmacologic doses are required for 
this effect, which is apparently not mediated by cyclic 
AMP. 20,21 
A number of functions within the central nervous 
' 
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system have recently been ascribed to the neurohypophyseal 
peptides; this has been substantiated somewhat by anatomic 
localization of significant amounts of vasopressin and neuro- 
physins in various regions outside of the classic supraoptico- 
10 12 22 
and paraventriculo-neurohypophyseal pathways. ’ ’ For 
example, one collateral pathway from the magnocellular 
nuclei leads to the zona externa of the median eminence 
where local release results in very high concentrations of 
AVP in the portal circulation to the adenohypophysis. The 
demonstration of this anatomical arrangement, combined with 
extensive pharmacologic studies, has given credence to a 
12 23 24 
physiologic role for AVP in stimulating release of ACTH. ’ ’ 
Demonstration of vasopressin in the hippocampus and parts 
of the limbic system has bolstered experimental evidence in 
rats that the neurohypophyseal peptides play important roles 
in long-term memory consolidation and in development of 
22 25 26 
tolerance to opiates. ’ ’ In addition, both the pres¬ 
ence of a blood-CSF barrier to AVP and the poor correlation 
sometimes found between simultaneous plasma and CSF hormone 
levels under both normal and, especially, pathologic con¬ 
ditions (subarachnoid hemorrhage, in particular) have been 
regarded as evidence that AVP is secreted directly into 
the CSF, where it may regulate the permeability of brain 
2 7 9R 
capillaries to water. ’ 
While it is fairly well established that vasotocin's 
role in lower land vertebrates parallels that of AVP in 
' 
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mammals--both produce antidiuresis by an adenylate cyclase- 
mediated alteration of epithelial permeability to water-- 
its role in marine vertebrates is not understood. Hampered 
by our ignorance of the mechanisms of osmotic homeostasis 
in these organisms, investigators have been unable to find 
an analogous effect on epithelial permeability, but have 
noted potent effects on gill blood flow and glomerular 
filtration rate. Should these vascular effects of the 
neurohypophyseal peptides prove to be physiologically impor 
tant in the maintenance of osmotic homeostasis in the phylo 
genetically older marine vertebrates, the unexplained yet 
potent vascular effects in mammals might easily be regarded 
as vestigial.1 
AVT may also act as a reproductive hormone in some 
land vertebrates, probably in a facilitative capacity 
analogous to oxytocin's role in mammalian parturition. Endo 
genous physiologic actions of the oxytocin-like peptides in 
1 2 
the lower vertebrates have yet to be identified. ’ 
The pineal gland of a number of vertebrates also 
contains AVT. Pavel and his coworkers, on the basis of a 
complex bioassay, have reported that all mammals that they 
have examined to date--including man--contain AVT (except 
for Suina, which have lysine-VT). Specialized ependymal 
cells in the pineal recess are involved in synthesis and 
storage, while the pineal hormone melatonin triggers re¬ 
lease of AVT into the CSF, from which it carries out its 
* 
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purported sleep-inducing and antigonadotrophic actions. 
These findings could be explanatory for an extensive litera¬ 
ture detailing the pineal's involvement in circadian rhythms 
33-35 
and gonadal development. Unfortunately, however, 
attempts to confirm the presence of vasotocin in mammals by 
highly specific radioimmunoassay have met with only varying 
36 30 
success.-3 Until this issue is resolved, Pavel's provoca¬ 
tive findings will have doubtful significance. 
Neurohypophyseal Hormones and the Eye-Effects on the Pupil 
Investigators early in the century began to examine 
the actions of posterior pituitary extracts on the eye. 
Their efforts were probably first inspired by the pupillary 
effects of the adrenal medullary hormones. Consequently, 
and because of its easy accessibility to direct viewing, 
the pupil became the earliest focus of ocular experimenta¬ 
tion with neurohypophyseal extracts. The general consensus 
of this early work, summarized by Pollack in 1920, was that 
Pituitrin (posterior pituitary extract) generally produced 
mydriasis in the enucleated frog eye, and miosis when in- 
39 jected intravenously into mammals. Pollack himself ob¬ 
served mydriasis after conjunctival instillation into 
rabbit eyes, but miosis upon intravenous administration. 
These early investigators were greatly hampered by 
the state of ignorance concerning the multiplicity of active 
principles in the neurohypophysis, and by variability in 
' 
Page 10 
commercially available crude extracts. The separation of 
the posterior pituitary extracts into vasopressin and oxyto¬ 
cin in 1928 served to facilitate further physiological in¬ 
vestigations. Thus, Swan and Meyers in 1936, using the newly 
commercially available posterior pituitary fractions, found 
that conjunctival instillation of Pitressin in the rabbit 
would induce not a mydriasis, but an atropine resistant 
40 
miosis, while Pitocin would have no effect on the pupil. 
On a historical note, it might be of interest to 
comment here that this discovery of a direct miotic action 
of a peptide hormone occurred years before either Ambache's 
isolation of irin in 1954 or the recent demonstration of 
70 93 
the miotic activity of Substance P. * 
Schlaeppi (1940), attributing the contradictory re¬ 
sults of the past to differing doses and routes of adminis¬ 
tration, attempted to resolve the discrepancies by examin¬ 
ing the effects of intravenous, subcutaneous, subconjunctival, 
41 
and conjunctival instillation of Pitressin and Pitocin. 
/V 
While large doses of Pitressin in rabbits (10 units intra- 
* Units of Pitressin (the purified extract) or vaso¬ 
pressin (the synthetic preparation) actually correspond to 
units of pressor activity, tested by measuring the blood 
pressure response of the rat; antidiuretic activity should 
be identical to pressor activity unit for unit in Pitressin 
or vasopressin.3 
Unless otherwise specified, units of Pitocin (which 
in this work refers to the purified extract) and oxytocin 
(the synthetic preparation) are actually measured in an 
avian vasodepressor bioassay, which parallels uterine- 
stimulating activity.3 
' 
* 
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venously, 1-10 units subconjunctivally or 5 units by in¬ 
stillation) produced a marked atropine-resistant moisis last 
ing several hours, small doses of Pitressin (0.05 units sub¬ 
conjunctivally) produced a small mydriasis. Subcutaneous 
administration (5 units) produced a weak mydriasis peaking 
within the first 45 minutes followed by a somewhat stronger 
miosis. This pattern was explained by the relatively slow 
systemic absorption resulting from subcutaneous administra¬ 
tion, which results in a phase of low Pitressin plasma 
levels (manifested by mydriasis) followed by higher plasma 
levels (manifested by miosis) as more Pitressin is absorbed 
from the injection site. Pitocin, on the other hand, was 
found to act like weak Pitressin, producing mydriasis upon 
intravenous or subcutaneous administration (5 units) and 
41 
no effects on the pupil when administered locally. 
Schlaeppi also carried out some experiments in human 
subjects. Intravenous administration of Pitressin (8 units) 
in man produced about 3mm of mydriasis, beginning after 
two to three hours and lasting indefinitely. Subconjunctival 
Pitressin (10 units) also produced a long lasting mydriasis 
but conjunctival instillation had no effects. Corresponding¬ 
ly, Pitocin, which acted like a weak Pitressin in rabbits, 
41 had little or no effects in man. 
Thus, Schlaeppi's attempt to settle the issue of 
vasopressin's pupillary effects seems to imply at least a 
dual action--a dilatory effect in the low dose range and 
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a constrictive effect that predominates in the high dose 
range. Besides a 1949 paper in which Zwiauer and Bornschein 
mention in passing that they observed miosis following intra 
42 
venous injection of Pitressin (10 units) into rabbits, 
no further studies on the neurohypophyseal peptides' pupil¬ 
lary effects have appeared in the literature. 
The Neurohypophyseal Peptides and the Eye--Theoretical 
Considerations of Effects on Intraocular Pressure 
Before tackling the experimental literature concern¬ 
ing vasopressin's effects on intraocular pressure (IOP), it 
may be worthwhile to digress in order to comment on how vaso 
pressin might plausibly act to produce its IOP effects. 
Although a detailed discussion of aqueous dynamics will not 
be undertaken here, an attempt has been made to summarize 
some particularly relevant points. (Table 2) 
A few aspects require further elaboration: 
1) The most reasonable targets for a physiological action 
of vasopressin on IOP are the ciliary epithelium -- where 
transport processes or water permeability may be regulated-- 
and the outflow tracts-- where it may effect smooth muscle 
or myoepithelial contractility. 
2) Vascular effects are unlikely to produce long-lasting 
changes in IOP. Volumetric changes, resulting from local 
vasoconstriction or a sudden rise in systemic arterial pres¬ 
sure, have only transient consequences on IOP. Furthermore, 
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because aqueous humor formation depends primarily on ciliary 
epithelial active transport and not ultrafiltration, moderate 
changes in ciliary arteriole perfusion pressure and blood 
flow would probably not significantly alter aqueous inflow. 
Only in the unlikely event that vasopressin causes a lasting 
vasoconstriction sufficient to elminate almost completely 
the blood flow to the ciliary processes would aqueous humor 
secretion be significantly reduced and a long-lasting effect 
43 
on IOP result. 
3) "Plasma osmolarity," "pupillary block," and "episcleral 
venous pressure" are included for the sake of completeness. 
Plasma osmolarity changes have well-established, but tran¬ 
sient, effects on IOP. Pupillary block could only become 
significant if vasopressin exerted a strong miotic effect, 
unlikely under physiologic circumstances. Vasopressin may 
act to raise central venous pressure, and therefore episcleral 
venous pressure, in pathologic states such as water intoxica¬ 
tion (SIADPi) or shock, but also not under normal circumstances. 
Because vasopressin might have multiple sites of ac¬ 
tion, its net effect on IOP could vary considerably, depend¬ 
ing on dose and route of administration. The situation is 
complicated further by the use of anesthesia, which can 
significantly alter systemic and intraocular responses to 
vasopressin. (See Table 2) 
With these considerations in mind, it becomes clear 
that experimental effects of vasopressin must be interpreted 
. 
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very cautiously, both with respect to mechanisms of action, 
and with respect to implications for physiological signifi¬ 
cance. It is hoped that some of the pitfalls of past inves¬ 
tigations can in this way be avoided. 
Neurohypophyseal Peptides and the Eye--Past Investigations 
of Effects on Intraocular Pressure 
Numerous cases of abnormalities of IOP associated 
with derangements in pituitary function appeared in the 
literature in the early part of the century, prompting a 
search for a possible role for the neurohypophyseal hormones 
41 in regulation of IOP. These studies fell prey to the 
same difficulties encountered in the investigation of 
pupillary effects, but even more so, because of the greater 
inherent complexity of IOP regulation. The following example 
illustrates this point. 
44 'V 
Colle et al administered Pituitrin (3 units in¬ 
travenously) in the intact anesthetized dog, and observed 
a transient increase in IOP proportional to a simultaneous 
transient rise in arterial blood pressure. However, upon 
administering Pituitrin (5 units) in an isolated perfused 
dog head preparation, they instead noted a decrease in IOP 
* Units of Pituitrin, the extract of the posterior 
pituitary which contains both vasopressin and oxytocin, 
are actually measured as units of oxytocic activity, which 
parallels ADH activity. 
' 
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lasting for hours, associated with a decrease in local tem¬ 
perature that to them indicated local vasoconstriction. 
These experiments suggested to the investigators that 
Pituitrin causes a vasoconstriction-mediated hypotensive 
effect that is masked by its pronounced pressor effect in 
the intact animal. This explanation does not, however, ex¬ 
plain why the same ocular hypotensive effect was not un¬ 
masked in the intact animal once the blood pressure had 
receded to baseline levels. In fact, because of differences 
in dose--three vs. five units--and pharmacokinetics--intact 
circulation vs. an isolated perfusion system--the two ex¬ 
periments are not really comparable. It might also be 
noted here that anesthesia, used in the intact animal ex¬ 
periment, tends to augment the pressor response to vaso¬ 
pressin by inhibiting the normal baroreceptor reflexes. 
As with investigations of pupillary effects, vari¬ 
ability in the preparations of the hormones used for experi¬ 
ments may have contributed to discrepancies. For example, 
45 Cohen and Bothman observed no changes in the choroidal 
circulation of rabbits following intravenous injections of 
46 
Pituitrin (1 ampoule). In contrast, Wudka and Leopole 
used the somewhat purer preparation Pitressin (3-10 units 
per kilogram given intravenously) and observed, by direct 
viewing through a plastic uveal window in the proptosed 
rabbit eye, an immediate and marked vasoconstriction that 
especially affected choroidal arterioles and lasted several 
minutes. 
. 
. . ... . 
' 
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A general consensus eventually began to develop con¬ 
cerning vasopressin's action on IOP. Schlaeppi^ observed 
consistent lowering of IOP in both man and rabbits following 
administration of Pitressin, even in doses as low as 0.05 
units when injected subconjunctivally into rabbits. Pitocin 
was also observed to lower IOP in rabbits, but not in man. 
In partial confirmation of these findings, Becker and 
47 Christensen observed lowering of IOP, lasting 2-3 hours, 
following conjunctival instillation of Pitressin (2 units) 
in both normal and glaucomatous eyes. In both humans and 
rabbits the hypotensive effect was parallelled by a decrease 
in tonographically measured aqueous inflow, with observable 
48 iridial vasoconstriction in the rabbit. Moreover, upon 
repeated administration resistance rapidly developed simul¬ 
taneously to Pitressin's hypotensive and vasoconstrictive 
effects. These studies, combined with those of Colle et 
44 46 
al and VJudka and Leopold, all seemed to indicate that, 
in pharmacologic doses, vasopressin lowered IOP and reduced 
aqueous inflow, perhaps by means of a vasoconstriction- 
induced lowering of ultrafiltration-dependent aqueous for¬ 
mation. 
However, a trend in the opposite direction began to 
develop. Reports appeared, such as Weinstein's in 1950, 
claiming that posterior pituitary extracts increased the 
sensitivity of the response to the water provocative test 
49 for glaucoma. Although these claims were disputed by 
' 
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Leydhecker, interest had been stimulated in the possibility 
that vasopressin, in lower and more physiologic doses, 
acted to raise IOP. 
To test this possibility, Houle and Grant investigat¬ 
ed the interactions of ethanol and physiological doses of 
vasopressin on IOP.~^ Ethanol ingestion had previously 
been observed to lower IOP in glaucomatous patients. Since 
ethanol produces a well known diuretic effect by inhibiting 
release of AVP from the neurohypophysis, it appeared reason¬ 
able that its ocular hypotensive effect might also be 
caused by inhibition of AVP release. Houle and Grant found 
that subcutaneous administration of 0.5 units of vasopressin, 
a dose that was calculated to produce maximal antidiuretic 
but no vasoconstrictor effects, did indeed prevent the 
ethanol-induced lowering of IOP in glaucoma patients. 
Furthermore, the serum osmolarity changes did not in them¬ 
selves seem sufficient to account for the observed IOP 
effect. Therefore, a physiological role for vasopressin 
in maintaining IOP was suggested. 
Various mechanisms for AVP's putative role in IOP 
modulation were considered. Cardiovascular effects required 
high doses and so were probably not involved. Alterations 
in plasma osmolarity were being examined but seemed an un¬ 
likely explanation. However, an attractive hypothesis 
arose by drawing a parallel between the ciliary epithelium 
■' 
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in the eye and the tubular epithelium of the kidney--perhaps 
AVP exerted a direct epithelial effect on aqueous humor 
formation, just as it exerted a direct epithelial effect on 
urine formation. 
Berggren was unable to confirm this attractive idea 
5 2 
in his in vitro ciliary process preparation. Neither vaso¬ 
pressin (0.2 units per ml. of medium) nor oxytocin (0.1 units 
per ml.) had any effect on the rate of spontaneous ciliary 
process shrinkage monitored photographically in vitro. How¬ 
ever, even Berggren himself pointed out that the technique 
he used is better suited to demonstrate inhibition rather 
than stimulation of ciliary process transport. 
Subsequently, though, Cole and Nagasubramanian 
succeeded in demonstrating that vasopressin can stimulate 
short circuit current in an in vitro isolated ciliary body 
preparation, using concentrations low enough to be con¬ 
sistent with a physiological role for vasopressin in in¬ 
creasing aqueous humor formation in the rabbit. ^ According 
to their hypothesis, vasopressin, which has the property of 
stimulating sodium transport in amphibian bladder epithelium, 
also stimulates sodium transport by the ciliary epithelium 
of the rabbit, thereby increasing aqueous inflow and IOP. 
This mechanism would serve the purpose of preventing falls 
in IOP caused by dehydration or plasma hyperosmolarity. To 
further substantiate their arguments, Cole and Nasasubraman- 
53 
lan performed the following additional experiments: 
/ 
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1) They compared the relative capacities of several vaso¬ 
pressin analogs to stimulate short circuit current, and 
found that the order of their relative activities-- 
2 8 8 
Pitressin = LVP > Phe - Lys -VP > Ornithine -VP--parallels 
their antidiuretic potency (on an ADH units to pressor units 
basis). 
2) They expanded on the experimental model of Houle and 
Grant‘d and showed that Pitressin, administered intravenously 
in sub-pressor doses (400yU/kg/min), prevented the ocular 
hypotensive effects of ethanol loading in rabbits, indepen¬ 
dent of effects on serum pH or osmolarity. 
3) They showed correspondence between in vivo and in vitro 
g 
experiments by demonstrating that Orn -VP, which could not 
effectively stimulate short circuit current, also would not 
prevent the ocular hypotensive effects of ethanol in rabbits. 
Although their experiments do tentatively favor a 
role for vasopressin in stimulating aqueous formation, 
their arguments extolling the suggested parallels between 
this activity and the ADH effect have several flaws. First 
of all, there is little or no evidence that vasopressin 
stimulates epithelial sodium transport in the mammalian 
12 kidney. Secondly, Bentley in 1967 showed that the 
natriferic activity of synthetic vasopressin analogs in the 
toad bladder correlated most accurately with pressor activ- 
54 lty and not ADH activity. Finally, Cole and Nagasubra- 
manian confuse potency with efficacy when comparing the 
. 
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vasopressin analogs. Only a four-fold higher dose of Orn -VP 
is required to produce the same antidiuretic action as a 
given dose of Pitressin in the kidney.^ On the other hand, 
their data show no stimulation of short circuit current by 
8 5 Orn -VP even in concentrations 10 times the threshold con¬ 
centration needed for Pitressin's stimulatory effect. Thus, 
according to their data, the parallels drawn between vaso¬ 
pressin's renal and ciliary epithelial effects are not 
really warranted. 
However, it is important to emphasize the essential 
validity of their approach of combining a plausible in 
vitro assay with a fairly reliable and physiological in 
vivo experimental model. In fact, despite possible side 
effects of the ethanol, this rabbit model is especially 
attractive because probably the best way to demonstrate 
physiological action of a substance is to remove or inhibit 
the endogenous source before administering physiologic 
amounts of exogenous material. Unfortunately, Nagasubraman- 
ian, in further pursuing vasopressin's actions on IOP, failed 
to adhere to this principle, illustrating instead some of 
the pitfalls encountered by not establishing a well for¬ 
mulated paradigm in carrying out research. 
For example, to rule out the possibility that vaso¬ 
pressin might be mediating its antihypotensive effect by a 
decrease in outflow facility, Nagasubramanian performed con¬ 
stant pressure infusion experiments over the range of 20 to 
J 
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35 mm Hg. Intravenous infusions of vasopressin (400-1600yU/ 
min/kg) had no effect, while intracameral infusions at con¬ 
centrations of 50 yU/ml actually caused a decrease in out¬ 
flow facility. However, fundamental flaws in the experi¬ 
mental design are quite evident. First of all, if vaso¬ 
pressin's physiological role is to prevent IOP from falling 
to dangerously low levels under certain conditions, then 
possible effects on outflow facility should be examined at 
tensions below 20 mm Hg. Furthermore, vasopressin had been 
shown to produce an ocular hypotensive effect in rabbits 
only if endogenous vasopressin release had been suppressed 
53 by ethanol pretreatment. Perhaps vasopressin has an 
effect on outflow facility that is similarly dependent on 
pretreatment with ethanol. Nagasubramanian, however, only 
measured effects on outflow facility in rabbits that had 
not been treated with ethanol. Therefore, his experiment 
does not really address itself to the important question he 
set out to answer. 
In addition, some experiments are burdened with the 
use of nicotine to stimulate secretion of endogenous vaso- 
5 6 
pressin in ethanol loaded rabbits. In view of its potent 
and complex autonomic effects, though, it is unclear what 
advantages nicotine has over physiologic administration of 
vasopressin in the in vivo experimental model. 
Other experiments, employing close-arterial and in¬ 
travenous infusions of vasopressin, attempt to correlate 
' 
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changes in IOP with simultaneous changes in systemic arterial 
pressure and thermocouple-monitored uveal blood flow in the 
56 
anesthetized rabbit. The results confirm the previously 
held opinion that in high doses vasopressin lowers IOP in 
association with reductions in uveal blood flow. However, 
reductions in ciliary process blood flow are not thought to 
diminish aqueous humor secretion unless blood flow is re¬ 
duced to extremely low levels. Therefore, since these 
experiments do not provide absolute values for ciliary pro¬ 
cess blood flow rates, one cannot determine if the blood 
flow reductions are sufficient to account for decreased 
aqueous production and lowering of IOP. Nagasubramanian 
also employs infusions of physiologic doses of vasopressin, 
which reportedly produce neither IOP changes nor changes in 
thermocouple readings. These experiments, however, do not 
rule out possible effects of vasopressin on microcircula- 
tory distribution within the uvea; changes in which would 
not necessarily alter the net uveal blood flow rates moni¬ 
tored by the thermocouple. 
In the following study, Niederer et. al.~^ draw a 
5 6 
conclusion opposite to that of Nagasubramanian regarding 
the mechanism of the ocular hypotensive effect of pharma¬ 
cological doses of vasopressin. In this experiment, aqueous 
humor production is measured by monitoring 1-125 clearance 
from the anterior chamber using a collimated-beam photo¬ 
multiplier. The investigators report that a pharmacologic 
' ' , 
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dose (0.5 units) of LVP injected intravenously into the 
anesthetized rabbit produces a significant decrease in 
aqueous formation that lasts about twenty minutes. Because 
the observed rise in systemic arterial pressure dissipates 
within only five minutes, the experiment is interpreted as 
an indication that LVP's inhibition of aqueous formation 
is mediated by a direct effect on the ciliary epithelium. 
Unfortunately, neither do the authors provide any absolute 
values for aqueous humor formation nor do they monitor IOP; 
therefore it is difficult to assess whether a nociceptive 
response had occurred following the many intracameral injec¬ 
tions used by the investigators for mixing. Interpretation 
is further complicated by the use of urethane anesthesia 
and atropine pre-medication, both of which have potent 
autonomic effects. Host importantly, a systemic pressor 
response is an insensitive indicator of local vasoconstric¬ 
tive effects."^ Therefore, the interpretation of Nieaerer 
et al cannot be justified on the basis of their data alone. 
73 Recently, Gregory et al have studied the effects 
of vasopressin on adenylate cyclase activity in broken and 
intact cell preparations of rabbit ciliary processes. Vaso¬ 
pressin, in a wide range of pharmacologic concentrations, 
did not significantly affect the adenylate cyclase activity 
of ciliary processes, despite the fact that in the same in 
vitro system vasopressin caused a 36-fold rise in adenylate 
cyclase activity of toad bladder epithelium. The findings 
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of Gregory et a_l argue against the possibility that vaso¬ 
pressin exerts an ADH - like action upon ciliary epithelium. 
To summarize briefly, Pitressin or LVP in large 
doses seems to lower IOP^ ’ ^ ^ except when a systemic 
44 pressor response is induced. Evidence has been presented 
to purport that this effect is mediated either by vasocon- 
stnction, by a direct epithelial effect, or 
conceivably by an increase in outflow facility,^ but al¬ 
most certainly not by activation of ciliary epithelial 
73 
adenylate cyclase. Physiologic doses, on the other hand, 
505256 
may have no effect ’ ’ or may promote ciliary epithelial 
53 56 
sodium transport, ’ thereby stimulating aqueous formation, 
observed in vivo only when endogenous hormone levels have 
51 53 been suppressed by ethanol. ’ In relation to the 
pupillary effects of vasopressin, the IOP response seems 
more prominent, since investigators have usually failed to 
comment on any pupillary changes. 
As for other neurohypophyseal peptides, oxytocin 
has been noted in large doses to produce a small decrease 
41 in IOP and slight mydriasis. Neither vasotocin nor any 
of the newer potent and selective agonists and antagonists 
have been examined for effects on the pupil or IOP. 
Neurohypophyseal Peptides and the Eye--Some Untried 
Experimental Approaches 
With the advent of synthetic preparations of many 
' 
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peptide hormones, it has often been rewarding to re-examine 
phenomena which were studied in the past using crude ex¬ 
tracts that may have possibly contained unknown contaminants. 
This point is especially pertinent to the pupillary effects 
of the neurohypophyseal hormones, which have not been ex¬ 
tensively studied since 1940. 
In addition, because the neurohypophyseal hormones 
have multiple and complex pharmacologic activities, synthetic 
analogs have proved to be very useful in sorting out their 
diverse physiologic actions. For example, by using DDAVP, 
a nonpressor analog, to separate antidiuretic from pressor 
effects, Johnson, e_t al were able to demonstrate that AVP- 
induced inhibition of renin secretion and increase in renal 
electrolyte excretion are not secondary to increased tubular 
5 8 permeability to water. Bentley used analogs with varying 
ratios of pressor to antidiuretic activity to illustrate 
differences in the receptors mediating water permeability 
54 
and sodium transport in the toad bladder. Keppens and 
De Wulf used a variety of synthetic pressor agonists and 
antagonists to confirm that vasopressin-induced hepatic 
glycogenolysis is probably not mediated by an ADH-like 
receptor and correspondingly not mediated by adenylate cy- 
i 21 clase. 
To this author's knowledge, no work has been pub¬ 
lished using DDAVP to examine vasopressin's mechanism of 
action on IOP or the pupil. DDAVP has a ratio of antidiuretic 
- 
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to pressor activity of from 79 to 4500 (depending upon the 
dose used) in contrast to AVP' s ratio of about 1. The 
8-D-arginine residue somehow contributes to functional 
selectivity of the molecule by stabilizing its backbone 
through increased steric hindrance."* DDAVP is also a more 
potent antidiuretic agent than AVP on a molar basis and 
has a longer duration of action because deamination at 
amino acid position 1 prevents its normal enzymatic degrada¬ 
tion in target organs. Furthermore, DDAVP's oxytocic ac¬ 
tivity is negligible. Therefore, significant ocular actions 
of DDAVP would most likely be mediated by ADH-like receptor 
mechanisms, since pressor effects will be reduced consider- 
ab ly. 
Another approach would entail the use of selective 
antagonists to vasopressin. Although there are still no 
efficient antagonists to ADH activity, several highly selec¬ 
tive and potent antagonists to the pressor activity have 
recently been synthesized. The most potent to date is 
dCCl^)^“Tyr-(Me)-AVP, synthesized by Maurice Manning's group 
at the Medical College of Ohio. It has an antivasopressor 
"PA2" or 8.67 + 0.02 (i.e. 50% inhibition of pressor re¬ 
sponses in rats occurs at antagonist concentrations of 
“8 62 
10 ' M) and also exhibits a protracted effect. Furthermore, 
it is not endowed with any ADR antagonist activity and has 
very low agonist activity (0.31 units/mg) in rat anti- 
59 diuretic assays. 
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Besides using pharmacological approaches to sort out 
mechanisms of response to neurohypophyseal hormones in vivo, 
one might also benefit from employment of in vitro methods 
to eliminate sources of variability. Pupillary effects can 
6 0 be studied ideally in vitro, as demonstrated by Sears and 
by Soloway, et al. ^ The well studied effects of the auto¬ 
nomic nervous system and circulating catecholamines, as 
well as the less understood mechanisms of nociceptive 
responses, could potentially mask direct effects of ex¬ 
perimental agents on the pupil. Furthermore, vasopressin's 
vascular actions might also indirectly effect the pupil¬ 
lary response. By eliminating these sources of complica¬ 
tions, by providing a convenient means for precise adjust¬ 
ment of peptide concentrations and by allowing sensitive 
and quantitative continuous monitoring of pupil responses, 
in vitro studies can greatly add to our understanding of 
vasopressin's actions on the pupil. 
Finally, a variety of agents with known or suspected 
ocular actions can be used in conjunction with the neuro¬ 
hypophyseal peptides to preclude systematic errors. Further¬ 
more, comparison of the actions of other neuropeptides with 
those of neurohypophyseal peptides may prove especially 
fruitful when attempting to assess physiological or phylo¬ 
genetic significance. 
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EXPERIMENTAL 
Introduction 
The broad experimental objective of the present work 
is to establish methodological guidelines for characteriz¬ 
ing receptor mediation of intraocular actions of the neuro¬ 
hypophyseal hormones and possibly other neuropeptides. This 
approach involves thoroughly characterizing, with the help 
of in vitro studies, one relatively simple effect--pupil- 
lary constriction--that can be used as a reference point 
for investigating more complex actions, such as those on 
IOP. 
Specific experimental objectives include: 
1) Investigation of the effects of neurohypophyseal pep¬ 
tides on the pupil through the use of an isolated iris 
preparation. 
2) Characterization of the receptor mediation of the in 
vitro response through the use of analogs and a potent, 
highly selective synthetic antagonist. 
3) Examination of the effects of pharmacologic agents on 
the responses to neurohypophyseal peptides in vitro, in 
order to rule out possible mediation of the response through 
indirect mechanisms. 
4) Comparison of the actions of neurohypophyseal peptides 
with putative peptide mediators of pupillary responses. 
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5) Establishment of basic dose-response curves for the 
effects of intravitreal injections of neurohypophyseal pep¬ 
tides on the pupil and IOP, with emphasis on the use of 
DDAVP to separate vascular from non-vascular mechanisms. 
Materials and Methods 
The following chemicals were used: Lysine-vasopressin, 
oxytocin, vasotocin, arginine-vasopressin, substance P, cap¬ 
saicin, met-enkephalin, bradykinin triacetate, indomethacin, 
acetyl-B-methyl-choline bromide, 1-phenylephrine hydrochloride, 
Tween-20 (Sigma, St. Louis), substance P-fragment 4-11 octa- 
peptide, neurotensin (Boerhinger-Mannheim), l-deamino-8-D- 
arginine-vasopressin (DDAVP, Desmopressin, Ferring Pharma¬ 
ceuticals), and d^I^) ^Tyr-(Me) AVP , a synthetic vasopressor 
antagonist which was the generous gift of Dr. Manning. All 
peptides used were synthetic with the exceptions of vaso¬ 
tocin and met-enkephalin. 
In all experiments, 2 to 2% kg male New Zealand 
albino rabbits were used. 
The in vitro Isolated Iris Preparation 
Isolated iris preparations have proven useful to 
numerous investigators for determining pupillary responses 
to pharmacologic agents in the absence of interfering auto- 
6 0 
nomic and vascular effects. The present in vitro system 
is essentially identical to that used by Soloway et: al to 
* 
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investigate the actions of substance P on the iris. 
Dissection Procedure 
Anesthesia (urethane, 1,5-2 g/kg given intravenously) 
was used to permit enucleation in the live animal and ensure 
viability of the second iris hours later. Most animals also 
received sodium indomethacin (50 mg/kg given intravenously) 
at least 15 minutes before enucleation to prevent interfer¬ 
ence of endogenously-synthesized prostaglandins in the post¬ 
mortem pupillary response. 
After enucleation the cornea was circumferentially 
excised. Six longitudinal incisions from the posterior 
pole were made, creating six triangularly shaped scleral 
flaps arranged hexagonally around the iris, leaving a 3mm 
scleral margin from the limbus. The lens and any remaining 
vitreous were gently brushed away, and the preparation was 
pinned to a paraffin-covered cork surface, whereby the 
iris was stretched to a uniform circular shape. Two plastic 
0-rings with perforating connecting needles were used to 
mount the specimen through its scleral margin, thus allowing 
free movement of the iridial muscles. After placement in 
the perfusion chamber housed within the spectrophotometer, 
perfusion was immediately begun. Elapsed time from enuclea¬ 
tion to perfusion was about 10-15 minutes. 
In one experiment, in order to obtain an isolated 
dilator muscle preparation, the same procedure was carried 
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out, save for the use of a 5mm trephine to remove the 
sphincter muscle. 
Perfusion System 
The 1.2 ml iris chamber was continuously perfused at 
a rate of 3 mg/min with a modified Krebs-Ringer bicarbonate 
62 buffer solution with the following constituents (in milli¬ 
moles/liter) : NaCl 118, NaHC03 25, KC1 4.8, KH2P04 1.2, CaCl 
1.3, MgSO^ 1.2, glucose 10, ascorbic acid 1.0. Oxygenation 
and a pH of 7.3-7.4 were maintained by equilibration with a 
gas mixture of 95% 02/5%, C02- A water bath was used to pro¬ 
vide a constant chamber temperature of 25°C, monitored by 
a thermometer placed at the chamber outlet. A peristaltic 
pump maintained constant perfusion rates. 
In this system, which combines high oxygenation with 
rapid clearance of metabolic products, the iris remains 
viable for hours, as judged by its continued responsiveness 
to pharmacologic agents. 
In a few experiments some modifications were made. 
Tween-20 (0.5 mg/liter) was included in the perfusion solu¬ 
tion in a few of the later experiments to retard adsorption 
of peptides to tubing. Slower perfusion rates (l.Omg/min) 
were sometimes used to prevent rapid clearance of pharmaco¬ 
logically released peptides. Employment of any of these 
modifications will be noted when reporting results. 
. 
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Infusion of Test Substances 
Perfusion buffer was used to make up peptide solu¬ 
tions which were delivered at precise infusion rates by- 
calibrated, silicone grease-coated Hamilton syringes, driven 
by two independent Harvard pumps, allowing simultaneous 
infusions of up to 3 compounds. Steady-state chamber con¬ 
centrations were calculated by dividing the infusion rate 
of the compound (in moles/min) by the chamber perfusion 
rate (usually 0.003 liters/min). 
In many experiments, 60 second infusions of peptides 
were employed (see below). In order to determine the pharma¬ 
cokinetics of this technique, infusions of CoC^ solutions 
into the chamber were monitored spectrophotometrically by 
this author and found to obey first-order kinetics, con- 
61 
firming previous studies that employed fluorescein to 
demonstrate complete chamber mixing. Therefore, the chamber 
concentration C of a test substance at any given time after 
starting or stopping an infusion is described by differ¬ 
ential equations (1) and (2), respectively, and can be 
calculated expliticly using (la) and (2a), respectively 
(1) dC _ r r dt LI V (2) 
dC _ r r 
dt V 
(la) 
, , -It 
C=CI ( 1-e V (2a) C = -£t cFe V 
represents s teady-s-tate infusion concentration. 
' 
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CF represents the final chamber concentration achieved at 
the end of an infusion; V is the chamber volume (1.2 ml) and 
r is the perfusion rate; t is the elapsed time after starting 
or stopping the infusion. Accordingly, when the perfusion 
rate is 3ml/min, 92% of steady-state chamber concentration 
should theoretically be achieved by the end of a 60 second 
infusion, after which rapid wash-out occurs. For simplicity, 
the doses used in one-minute infusions will always be re¬ 
ferred to by their corresponding steady-state chamber con¬ 
centrations . 
Pupillometrie System 
Continuous pupil measurement was made photometrically 
by a Carey 16 spectrophotometer, using a wavelength setting 
of 540nm and a 3mm slit width. Holes of various known dia¬ 
meters were used to establish a standard curve which demon¬ 
strated a highly linear relationship between diameter and 
"7, transmittance." A calibrated chart recorder was used 
to continuously monitor absorbance. Absorbance values read 
from the chart were converted, using Beer's law, directly 
to "70 transmittance" which was used to calculate pupil 
diameter from the standard curve. This system thus provided 
a continuous permanent record of pupil diameter; changes in 
diameter as small as 25 microns could be reliably detected. 
Baseline pupil diameter showed a high degree of 
variability between preparations, ranging from about 2.5 to 
' 
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5mm. Semmlow et al demonstrated in humans that "pupillo¬ 
motor gain" varies with baseline diameter, peaking at 4 to 
^ 3 ^ / 
6 mm and tailing off at smaller baseline diameters. ’ 
Therefore, in order to compensate for variability in respon¬ 
siveness, pupillary changes are expressed as a percentage 
of baseline diameter. 
Technique of Infusion 
After placement in the perfusion chamber, the iris 
was left to equilibrate for about 10 minutes and usually 
_ £ 
displayed a slow dilation. Phenylephrine (1 x 10 M) was 
then infused continuously, often producing a further increase 
in pupil diameter. This low dose of phenylephrine was usually 
used throughout the rest of the experiment to provide dila¬ 
tor tone, which facilitated a return to baseline following 
constrictions. Finally, after the pupil achieved a stable 
baseline diameter, experimental infusions were begun. Pre¬ 
parations with baseline diameters of less than 2.5 mm were 
discarded. 
Three modes of experimental infusions were used. 
One method employed a 60 second infusion of test compound, 
after which the maximum resulting change in pupil diameter 
was noted. When the pupil returned to baseline diameter, 
another infusion could be begun. Infusions were separated 
by at least 12 to 15 minutes in attempt to avoid tachyphy¬ 
laxis. This technique produced fairly reproducible re¬ 
sponses, and was employed for establishing dose response 
■ 
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curves to compare relative potencies of peptides. 
Continuous infusions were sometimes employed, 
allowing the pupil to achieve a steady-state response to an 
equilibrium concentration of peptide. Although fairly long 
infusions were often required before the pupil achieved a 
steady state response, the technique did maximize sensitivity 
to a given concentration of compound and therefore this par¬ 
ticular approach was used to compare response-threshold con¬ 
centrations of various peptides. 
Infusions of intermediate duration were sometimes 
employed when it was desirable to increase response sensi¬ 
tivity without waiting for achievement of a steady-state 
response. 
Isolated Iris F.esponses to Neurohypophyseal Peptides 
Pupil responses to AVP, LVP, AVT and OT were de¬ 
termined using 60 second infusions. In addition, responses 
to continuous infusions were obtained for AVP and AVT. 
Effect of Vasopressor Antagonist 
In one preparation, d(CI^)(Me)-Tyr-AVP was tested 
for its effectiveness in antagonizing responses of the pupil 
to LVP and substance P-octapeptide. 
Isolated Iris Dilator Muscle Preparation 
Responses of the pupil to LVP were tested in one 
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iri's in which the sphincter muscle had been removed with 
a trephine. Viability of the preparation had been tested 
with phenylephrine. 
Isolated Iris Responses to Other Neuropeptides 
Pupillary responses to 60 second infusions of sub¬ 
stance P (SP), SP-octapeptide, bradykinin, neurotensin, and 
met-enkephalin were tested. Because pupil responses to 
bradykinin, neurotension and met-enkephalin were weak, inter¬ 
mediate-length infusions ( > 60 seconds) were also employed 
to increase response-sensitivity. 
Indomethacin Pretreatment 
Indomethacin pretreatment (see "Dissection Pro¬ 
cedure") was sometimes withheld to determine what effects 
endogenous prostaglandins might have on the in vitro pupil¬ 
lary responses to neurohypophyseal peptides (AVT and LVP) 
and bradykinin. 
Capsaicin Depletion Experiments 
Capsaicin is known to deplete primary sensory 
65 
neurons of substance P, and may reduce the magnitude of 
66 both the ocular nociceptive response to nitrogen mustard 
67 68 
and neurogenic or bradykinin induced inflammation in 
the skin. 
Capsaicin was used here to produce a pharmacologic 
"sensory denervation" in vitro,in order to determine whether 
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sensory neurotransmitters are involved in the pupil's re¬ 
sponses to vasopressin and other peptides. Capsaicin pro¬ 
duces its own miosis in vivo, which probably is mediated by 
69 
released neurotransmitters. This phenomenon greatly facili¬ 
tated "chemical denervation" in the in vitro system. Infus¬ 
ions of capsaicin (usually about 0.4mg/ml for 10-20 seconds) 
were simply repeated until they failed to produce pupillary 
constriction, at which point the preparation was assumed to 
be pharmacologically denervated. Note that slow perfusion 
rates (1 mg/min) were used during these capsaicin infusions, 
in order to retard clearance of the released neurotransmitt¬ 
ers and thereby accentuate the pupillary constriction, which 
as a result provided an even more sensitive guide to adequate 
neurotransmitter depletion. 
Pupil responses to various peptides (LVP, brady- 
kinin, substance P) were then determined in the "sensory 
denervated" preparation. 
Effects of Neurohypophyseal Peptides on Pupil Size and IOP 
in vivo 
In deciding upon the route of administration for 
investigating the actions of the neurohypophyseal peptides 
on the pupil and IOP, several alternatives were considered. 
Intravenous administration is probably the most physiologic 
route of administration, but can produce systemic effects 
that may confuse interpretation of the results. Systemic 
■ 
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complications can be somewhat reduced by using close-arterial 
infusions. This technique, however, suffers from technical 
difficulty and the need for general anesthesia. Intracameral 
administration is also technically difficult, has a high 
risk of activating ocular nociceptive mechanisms, and is 
probably not physiologic. Conjunctival instillation is also 
not physiologic; it most probably leads to considerable 
systemic absorption and provides very uncertain pharmacologic 
delivery. 
The intraocular responses to neurohypophyseal 
peptides (LVP, AVT, OT and DDAVP) and substance P were deter¬ 
mined following intravitreal injections. This route of ad¬ 
ministration was chosen for the following reasons: 
1) simplicity 
2) availability of the contralateral eye as a control 
3) the relative avascularity of the vitreous minimizes 
systemic absorption 
4) lack of necessity for general anesthesia. 
The main objections are: 
1) there is uncertain pharmacologic delivery to the sites 
of action 
2) there is the danger of traumatizing the eye 
3) it is probably a non-physiologic route of administration. 
The first objection is dealt with by using intra¬ 
vitreal injections of substance P as a control since its 
' 
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molecular weight is similar to that of the neurohypophyseal 
peptides, and its actions on IOP and pupil size, via other 
routes of administration, have been well characterized.^^5 
Meanwhile, an effort is made to minimize the second objection 
by care in the technique and examination of the eye for signs 
of traumatic injury. 
Finally, the present work does not attempt to es¬ 
tablish physiologic roles for the neurohypophyseal peptides; 
instead, the emphasis is first placed upon characterization of 
pharmacologic responses by using relatively large doses and 
rather artificial means of administration. 
Intravitreal Injections--Procedure 
The rabbit was calmed and the eye proptosed by 
exerting pressure with the blunt end of a cotton tip appli¬ 
cator just above the inferior orbital rim while simultaneous¬ 
ly exerting digital counter traction on the superior aspect 
of the globe through the upper lid. Then, after instilla¬ 
tion of a local anesthetic agent (0.5% proparacaine HC1) 
at the injection site, usually about 5mm from the limbus, 
10 yl of fluid were delivered intravitreally using a Hamilton 
precision syringe fitted with a 30 gauge needle. Care was 
taken to avoid obvious large surface vessels, and the needle 
was directed slightly posteriorly in order to avoid hitting 
the lens. After the injection, all pressure on the globe 
or orbit was removed and the needle swiftly withdrawn to 
’ 
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prevent extrusion of vitreous. 
In each rabbit, the right eye received the test 
substance diluted to the desired concentration with isotonic 
saline. The left eye received an injection of saline and 
served as a control. Pre-injection baselines of IOP and pup 
diameter were recorded, and after the injection IOP, pupil 
diameter, and any signs of ocular irritation or injury were 
recorded. 
IOP measurements were made using an Alcon Applana¬ 
tion Pneumotonometer which had previously been manometrical- 
ly calibrated versus water for the rabbit eye. Proparacaine 
HC1 (0.5%) was instilled conjunctivally in each eye before 
tonometry. 
Pupil size was estimated by eye under ordinary 
room lighting conditions. Special care was taken to provide 
equal illumination to both eyes because the rabbit's pupil- 
72 lary light reflex displays poor consensuality. 
Analysis of Data 
Among structural analogs of the neurohypophyseal 
peptides, when one pharmacologic activity parallels another 
(e.g. avian vasodepressor parallels oxytocic; glycogenolytic 
parallels pressor) the two activities are thought to be 
21 
mediated by the same or a similar receptor. 
The present work attempts to determine whether 
. 
. 
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the receptor by which vasopressin exerts its pupillary effect 
is closely related to the receptor for either pressor, ADH, 
or oxytocic activities. The approach is to statistically 
analyze the correlations between pupillary effects and pep¬ 
tide doses, when doses are expressed as units of either 
pressor, ADH, or oxytocic activity; conversions from moles 
to units of activity are based upon values from the litera¬ 
ture. (Table 1) 
Two mathematical models are used. One model employs 
linear regression analysis of the relationship between pupil¬ 
lary response (the dependent variable) and the logarithm of 
the dose; high covariance exists among the independent var¬ 
iables -- log units of pressor, ADH, and oxytocic activity -- 
so that both simple and multiple regression analysis is per¬ 
formed . 
The other model attempts to compensate for obvious 
anatomical features which impose theoretical limits on pupil¬ 
lary response by employing the algebraic formalism of the 
Michaelis-Menten equation; "V " can be set at an approp- 
msx 
riate maximal pupillary response. The formalism is carried 
further by the use of the "Lineweaver-Burk" equation to ex¬ 
press the dose-response relationship in such a manner that 
both simple and multiple linear regression analysis can be 
performed. Such analysis derives a value for "K^" which is 
strictly defined in the present study as the dose of neuro¬ 
hypophyseal peptide needed to evoke a half-maximal pupillary 
response. 
' 
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RESULTS 
Response of the Isolated Iris to Neurohypophyseal Peptides 
All four neurohypophyseal peptides examined in vitro 
(AVP, AVT, LVP and OT) produced dose dependent pupillary 
constriction. Figure 2 clearly shows the relative potencies 
of the peptides (on a molar basis) using 60 second infusions. 
A similarly obtained dose-response curve to substance P is 
included for comparison. Typical tracings from the chart 
recorder illustrate the time-course of the response (figure 
3). 
Continuous infusions of the two most potent agents, 
AVP and AVT, produced pupillary responses at threshold con¬ 
centrations of 1 x 10 (n=l) and 2 x 10 (n=2) , re¬ 
spectively (figure 2). As a comparison it is interesting 
61 
to note that Soloway et al observed a threshold concentra¬ 
tion of 2.3 x 10 for substance P effects in the same in 
vitro system. 
A cursory examination of figurd 2 reveals that the 
relative potencies of the neurohypophyseal peptides in pro¬ 
ducing pupil constriction correspond to their relative 
pressor activities: AVP > AVT > LVP > OT. This relation¬ 
ship is further examined by converting infusion concentra¬ 
tions to units of either pressor, ADR, or oxytocic activity 
using values obtained from the literature (Table 1). Figures 
4 and 5 display in this manner the results obtained with ail 
' 
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four neurohypophyseal peptides. The aggregate relationship 
displays a high degree of linear correlation with pressor 
activity: R=0.818, 95% confidence levels are 0.681 - 0.900, 
standard error of estimate = 7.687 % constriction. A small 
degree of correlation with oxytocic activity (P. r 0.44), was 
found by multiple regression analysis to be accounted for 
by covariance with pressor activity (.418) (figure 5). It 
should be noted that because ADH activity equals pressor 
activity in all the peptides used for in vitro studies, it 
is theoretically impossible to separate the two effects in 
this analysis. However, ADH activity will be shown to be 
a rather weak determinant of pupil size. 
Another approach used to describe the data was based 
upon mathematical modeling akin to Michaelis-Menten enzyme 
kinetics. This model may have more intrinsic biological 
relevance than rather arbitrary linear models. The variable 
V ("enzyme velocity") is adapted to describe "%> pupil con¬ 
striction," while S (substrate concentration) is expressed 
as pressor units; a value for "V"max is assigned at 90% pupil 
constriction. The dose-response relationship is displayed 
as a Lineweaver-Burk plot (Figure 6); regression analysis 
reveals a correlation coefficient (R=0.828, 95% confidence 
limits 0.688-0.909,p<.001) slightly higher than the one ob¬ 
tained above with the simple linear-log model. A "K^" of 
13.46 ± 1.65 pressor units/liter (corresponding to approxi¬ 
mately 12 -t 1.5 nM for AVP) is obtained with this analysis. 
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Isolated Dilator Preparation 
The isolated dilator preparation did not respond to a 
6 minute infusion of LVP at 5 x 10 ^M, a dose that produces 
a maximal constriction in the intact preparation. The iso¬ 
lated dilator preparation did respond appropriately to an 
infusion of phenylephrine (1 x 10 ^M) by dilating 4.87,, 
thereby demonstrating viability of the preparation. 
The Effects of a Vasopressor Antagonist on the Isolated Iris 
At concentrations as high as 2 x 10 the antagonist 
by itself produced no pupillary response. However, a four 
minute infusion of antagonist (1 x 10 ^M) produced a 257> 
_ g 
dilation during a continuous infusion of LVP (1 x 10 M). 
Furthermore, during continuous infusions of antagonist 
(2 x 10 ^M) all responses to LVP (up to 1 x 10 ^M, infused 
continuously), were completely abolished. Furthermore, even 
after the infusion of antagonist had been stopped, responses 
_ g 
to LVP (2.5 x 10 M, 60 second infusions) were abolished for 
at least 15 minutes. 
This antagonistic activity was specific for vasopressin 
agonists; the antagonist in concentrations up to 4 x 10 
had no effect on responses to substance P octapeptide. 
Response of the Isolated Iris to Other Peptides 
Responses to 60 second infusions of substance P were 
61 
generally in good agreement with the data of Soloway, et al. 
(see figure 2). 
. 
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Substance P-(4-ll) octapeptide produced dose-dependent 
pupil constriction as well. Its potency was comparable to, 
if not slightly greater than, that of substance P; in one 
- 8 preparation, for example, substance P octapeptide (1 x 10 M, 
60 sec. infusions) produced constrictions of 32.46 + 1.7 870 
(mean + S.E.M.). 
Sixty second infusions of bradykinin produced pupillary 
_ g 
constrictions at concentrations as low as 1 x 10 M, but 
the response was subject to rapid tachyphylaxis (figure 7). 
Furthermore, bradykinin demonstrated markedly reduced potency 
after Tween-20 had been incorporated into the buffer solution. 
Neurotensin produced only weak constrictions (3.22- 
4.817o) at relatively high concentrations (4 x 10 ^M, 3-5 
minute infusions) in one preparation. 
Met-enkephalin produced no consistent pupillary re¬ 
sponses in concentrations as high as 4 x 10 (60 second 
infusions) in four separate preparations. 
Indomethacin Pretreatment 
Withholding indomethacin pretreatment produced no sig¬ 
nificant differences in responses to AVT (one animal), LVP 
(two animals) or bradykinin (two animals). 
Capsaicin Induced Densensitization 
In five preparations, the mean pupillary constriction 
produced by in vitro capsaicin treatment was 38.11 (+ 4.86)%. 
' 
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These "denervated" preparations continued to respond nor¬ 
mally to phenylephrine, LVP, and substance P octapeptide. 
However, pupillary constriction in response to bradykinin 
(6 minute infusion at 10 ^M) was abolished in a "denervated" 
preparation, while a 12°/0 constriction was observed in the 
"non-denervated" isolated iris of the same animal. 
Pupillary Responses to Neurohypophyseal Peptides in vivo 
All four neurohypophyseal peptides tested (AVT, LVP, 
OT, DDAVP) produced a dose-dependent miosis (figure 8). 
A typical time course to a series of injections is shown in 
figure 9. Substance P produced maximal miosis after intra- 
vitreal injections of 1.0 (n=l) and 0.1 (n=2) yg. 
Results were analyzed in the same manner as described 
above for in vitro pupillary responses. Because DDAVP was 
used in the in vivo experiments, the relationships between 
miosis, ADH activity, and pressor activity could be clearly 
sorted out (figures 10 and 11). While there was a relatively 
high correlation between miosis and pressor activity 
(R = 0.732, p < .001) there was no significant correlation 
between miosis and ADH activity (R = 0.27, p = .16). A 
high correlation was also found between miosis and oxytocic 
activity (R = .749, p < .001), but this relationship is 
accounted for by high covariance between pressor activity 
and oxytocic activity in the peptides used in vivo (R = 
0.613). Moreover, multiple linear regression reveals no 
■ 
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significant partial correlation coefficient for oxytocic 
activity (R = .292, p = .132), whereas the partial correla¬ 
tion for pressor activity is significant (R = .568, p < .002). 
Interestingly, the "Lineweaver-Burk" analysis dis¬ 
played best the superiority of the relationship between 
miosis and pressor activity. The respective bivariate corre¬ 
lation coefficients were: for pressor activity .708, p < 
.001; for ADH activity 0.543, p = .006 and for oxytocic 
activity .238, p = .263. Furthermore, it should be noted 
that the correlation coefficient for ADH activity is only 
due to very high covariance with pressor activity (.932). 
When a "V " of 6mm miosis was assigned, a "K " of 24.6 + 
max ° m — 
4.8 mUnits pressor activity (corresponding to 57 nanograms 
of AVP) was obtained. 
Effects of Neurohypophyseal Peptides on IOP in the Rabbit 
DDAVP does not appear to affect IOP significantly at 
the doses used (.01, .1 and lug) for intravitreal injections 
(Table 3). 
LVP (0.2 units) produced a small fall in IOP in two 
animals (4.5 + 2.13 mmHg); the response was maximal about 
two hours after the injection. In contrast, 2.5 units of 
oxytocin produced a rise in IOP (4.5 + 0.71 mm Hg) in two 
animals. In one animal the IOP increase peaked at 2, 9, 
and 27 hours while in the other animal the maximum increase 
occurred only at 27 hours; IOP returned to baseline by 36 
• 
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hours in both. There was no consisent relationship between 
A 
IOP response and miosis. Therefore, the unusual time course 
of the response and its occurrence in only two animals make 
it difficult to draw any conclusions from the data concern¬ 
ing the effect of oxytocin on IOP. 
Otherwise, because of large standard errors and small 
sample size, no significant patterns emerge. Multiple linear 
regression analysis reveals no significant correlations be¬ 
tween IOP changes and pressor, ADR, or oxytocic activity, 
nor any significant relation between miosis and IOP. 
The substance P injections all produced transient 
increases in IOP (7 + 0.4mm Hg), coincident with onset of 
maximal moisis. Stjemschantz et_ al have shown that this 
increase in IOP is probably secondary to pupillary block.^ 
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DISCUSSION 
Response of the Rabbit Iris to Neurohypophyseal Peptide 
The neurohypophyseal peptides are known to contract 
smooth muscle in a variety of tissues (see Introduction). 
Their contractile effects in vascular smooth muscle are 
thought to be mediated directly by an increase in the cyto¬ 
solic concentration of calcium ions.^ 
The present work clearly demonstrates that the neuro¬ 
hypophyseal peptides exert potent contractile action on the 
sphincter muscle of the rabbit iris; this confirms the work 
40 
of Swan and Meyer with Pitressin. Schlaeppi also observed 
miosis with large doses of Pitressin, but he reported that 
both Pitocin and small doses of Pitressin (0.05 units, 
injected subconjunctivally) produced a weak mydriasis. In 
the present work oxytocin demonstrated only miotic activity 
both in vivo (0.250 to 2.5 units, given intravitreally) and 
in vitro (0.004 to 0.4 units/ml). Furthermore, even doses 
as low as 0.02 units of LVP or 0.01 ug of DDAVP (which 
corresponds to only 0.00011 units of pressor activity) 
produced no mydriasis in vivo, while AVP tested at concen¬ 
trations as low as 5 x 10 never caused any dilation 
in vitro. Nor were any effects on the isolated dilator 
muscle observed. Therefore, the neurohypophyseal peptides 
seem to exert their pupillary actions solely on the iris 
■ 
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sphincter. 
A variety of indirect mechanisms by which the neuro¬ 
hypophyseal peptides may produce their actions on the pupil 
have been ruled out. The lack of influence of indomethacin 
pretreatment probably indicates that prostaglandins do not 
mediate the response. Because LVP, unlike bradykinin, re¬ 
tained its miotic efficacy following capsaicin treatment, 
it is unlikely that sensory neurotransmitters are signifi¬ 
cantly involved in the response. Because the neurohy¬ 
pophyseal peptides were effective both in vivo and in vitro 
the pupillary response is not related to actions on the vas 
culature of the iris. The response is also probably not 
41 
cholinergically mediated, because both Schlaeppi and 
42 
Swan and Meyer reported it to be atropine resistant. 
In conclusion, although several of the experiments in this 
work must be considered preliminary, it appears likely that 
the neurohypophyseal peptides are acting directly upon the 
smooth muscle of the iris sphincter. 
This conclusion is further substantiated by the re¬ 
ceptor characteristics of the response. Determination of 
the identity of the receptor was based upon analysis of the 
pupillary effects of several analogs in terms of their 
known potencies in producing ADH, pressor, or oxytocic 
effects. Such analysis is facilitated by the use of ana¬ 
logs with varying ratios of activities: e.g. DDAVP (high 
A:P and A:0 ratios) and OT (high 0:A and 0:P ratios). An 
* 
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even greater boon to receptor analysis is the possession of 
a specific antagonist such as dCCt^)^-Tyr-(Me)-AVP, which 
has an antivasopressor pA£ of 8.62 but does not antagonize 
ADH effects; in fact it possesses some small ADH activity 
(0.31 units/mg). Mediation of the miosis by a pressor-like 
receptor was thus demonstrated in several ways: 
1) The elimination of in vitro responses to LVP with the 
vasopressor antagonist ruled out any possible significant 
contribution of ADH activity toward producing miosis. 
2) Within both mathematical models used for analysis of the 
data, (linear-logarithmic and "Michaelis-Menten"-"Lineweaver- 
Burk"), the in vitro pupillary constrictions correlated 
with the concentration expressed as units of pressor activity 
per liter (R = 0.82, p < .001 and R = 0.83, p <.001, respec¬ 
tively). Furthermore, multiple linear regression within 
both models reveals a highly significant partial correla¬ 
tion coefficient for pressor activity (R = 0.78, p < .001 
and R = 0.72, p < .001, respectively) in contrast to that 
for oxytocic activity (R = 0.19, p = 0.26 and R = 0.41, 
p = .02, respectively). 
3) The range of structural analogs used in the in vivo 
experiments (DDAVP, LVP, OT, AVT), facilitated elimination 
of both oxytocic activity and ADH activity as contributing 
to the response. Multiple linear regression revealed that 
pressor activity had an important independent contribution 
to predicting miotic response (p < .002), whereas both ADH 
* 
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activity and oxytocic activity were not independently pre¬ 
dictive . 
Because receptor-characterization portrays the miosis 
as a pressor-like effect, a mechanism of action on the iris 
sphincter muscle analogous to that in vascular smooth muscle 
is favored. 
Effects of the Neurohypophyseal Peptides on 10P 
The fall in IOP noted upon intravitreal administration 
of a supraphysiologic dose of LVP (0.2 units) in two animals 
is in agreement with a number of previous studies in which 
large doses of Pitressin or LVP were administered by a 
variety of routes. In order to shed some 
light on the mechanism of this effect, DDAVP was administer¬ 
ed intravitreally in a total of 13 animals, in a range of 
doses corresponding to .04 to 4 units of ADH activity and 
.00011 to .011 units of pressor activity. Because no 
effect on IOP was noted (Table 3), it is unlikely that an 
ADH receptor mediated mechanism is responsible for vaso¬ 
pressin's classic pharmacologic hypotensive effect. This 
conclusion is consistent with the failure of Gregory et al 
to demonstrate significant adenylate cyclase activation 
73 by vasopressin in ciliary epithelium. However, although 
an action on ciliary epithelium mediated by another second 
messenger has not been ruled out, it seems that some more 
plausibility is now established for the argument that 
; 
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vascular effects might mediate the pharmacologic effect of 
44,46,47,48,56 
vasopressin on IOP. 
The present work has made no direct attempt to inves¬ 
tigate physiological actions of vasopressin on IOP. Nor 
has a physiologic role for an ADH receptor mediated action 
on the ciliary epithelium been ruled out by the negative 
results with DDAVP, since circulating levels of endogenous 
hormones may have already been sufficient to produce maximal 
epithelial effects in the experimental animals. 
The dearth of literature concerning intraocular ac¬ 
tions of oxytocin and vasotocin has already been mentioned. 
The isolated finding obtained with these hormones in the 
present study represent only a preliminary attempt to in¬ 
vestigate their effects on IOP. It is especially difficult 
to draw any further conclusions concerning the effects of 
neurohypophyseal hormones on IOP because statistical analysis 
failed to establish any significant trends relating IOP 
changes to either ADH, pressor, or oxytocic activity. 
Effects of Other Neuropeptides on the Iris 
In the present work, the pupillary effects of the 
neurohypophyseal peptides were compared to those of several 
other neuropeptides. 
Substance P has proven to be useful in assessing the 
pupillary effects of the neurohypophyseal peptides in 
several ways. Its known potent actions on the pupil were 
. 
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used to confirm adequate pharmacologic delivery of neuropep¬ 
tides from intravitreal injections.^5^>71,74 Furthermore, 
the dose-response curve obtained with substance P in this 
author's hands could be compared to results published in 
the literature to assess the general reliability and accuracy 
of the in vitro pupillometric system.^ 
Substance P is especially interesting in that it has 
so much in common with the neurohypophyseal peptides. Both 
have similar molecular weights (v 1380 for substance P, 
%1080 for vasopressin); both constitute a family of structur¬ 
al analogs widely distributed among vertebrates: 1,75 both 
76 77 
may be CNS neurotransmitters or "neuromodulators," ’ and 
both produce complex behavioral effects that interact sig- 
nificantly with opiates. In certain respects they 
appear to be physiological antagonists: substance P is 
79 
a potent vasodilator while vasopressin is a vasoconstrict- 
78 
or; substance P potentiates opiate analgesia in low doses, 
2 6 
while vasopressin seems to promote opiate tolerance; 
substance P generally promotes diuresis and natriuresis 
8 5 
while vasopressin is potently antidiuretic. 
The two peptides have very similar effect on the 
rabbit iris. Both seem to exert their effects directly on 
the smooth muscle of the iris sphincter. Moreover, they 
seem to display very similar potencies in vitro. The 
in vivo studies, on the other hand, indicated that sub¬ 
stance P may exert a somewhat more protracted effect on the 
‘ 
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pupil than vasopressin; this observation may be related to 
differential vulnerability of the peptides to enzymatic 
degradation in the vitreous. 
The major difference between the pupillary effects of 
the two peptides lies in their physiologic role. Substance 
P has been demonstrated by radioimmunoassay both in the 
81 
normal rabbit iris and in the aqueous humor following 
antidromic stimulation of the trigeminal nerve.^ There¬ 
fore, its miotic action probably plays a physiologic role, 
most likely in the ocular nociceptive response. On the other 
hand, comparable data concerning the presence of neurohy¬ 
pophyseal hormones in the eye are not available; the exis¬ 
tence of a locus of these hormones containing sufficient 
amounts to cause miosis is a highly speculative and unlikely 
conjecture. Vasopressin exerts its maximal antidiuretic 
-12 12 
action at plasma levels on the order of 10 M. Even a 
maximal hypovolemic stimulus to vasopressin release does 
-11 3 
not produce levels much in excess of 5 x 10 " M, which 
is below the in vitro threshold concentration for AVP's 
effects and much lower than the in vivo "K " for AVP of 
— - m 
- 8 1.4 x 10 M (calculated by assuming a volume of 4 ml for 
the rabbit eye). Therefore, in contrast to substance P, 
the miotic effects of the neurohypophyseal peptides are 
probably of no physiologic significance in mammals. 
Interestingly, the 4-11 octapeptide fragment of 
substance P also constricts the isolated iris; in fact its 
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potency may even be slightly greater than the native pep¬ 
tide in vitro. This raises the possibility of using structur¬ 
al analogs to substance P to help sort out complex physiolog¬ 
ic effects in a manner analagous to the experimental applica¬ 
tions of neurohypophyseal hormone analogs. 
It should also be noted that substance P-octapeptide 
helped demonstrate the pressor receptor specificity of the 
inhibitory effects of dCCIb,)^-Tyr-(Me)AVP. Because the 
response of the isolated iris to substance P-octapeptide was 
not diminished by concentrations of dCCI^) ^-Tyr- (lie) AVP that 
completely blocked the effects of LVP, one can conclude 
that substance P and vasopressin exert their direct smooth 
muscle actions on the iris sphincter through different 
receptors. 
The in vitro pharmacological activity of bradykinin 
presented a striking contrast to that of vasopressin or 
substance P by displaying marked tachyphylaxis and vulner¬ 
ability to capsaicin-induced desensitization. Interestingly, 
Cole and Unger also commented on the tachyphylaxis to brady¬ 
kinin 's effects on IOP and the pupil in experiments employ- 
82 
ing closed circuit intracameral perfusion in vivo. This 
marked tachyphylaxis is suggestive of bradykinin-induced 
depletion of a limited endogenous pool of mediators of its 
83 
response. Eakins et al reported that indomethacin pre¬ 
treatment markedly inhibited bradykinin’s stimulation of 
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miosis and increase in aqueous humor protein; they there¬ 
fore argued in favor of a role for prostaglandins in mediat¬ 
ing bradykinin's response. However, the present work found 
that indomethacin pre-treatment of the rabbit with a dose 
(50mg/kg intravenously administered) previously demonstrated 
84 
to completely inhibit cyclooxygenase, has no effect on 
bradykinin-induced miosis; this finding is in agreement with 
82 
Cole and Unger, who also noticed no blockade of brady¬ 
kinin's actions on the eye by indomethacin. 
The observation of in vitro capsaicin-induced desen¬ 
sitization of the iris to bradykinin is consistent with the 
putative mediation of bradykinin's nociceptive actions by 
sensory neurotransmitters . ^ ^ > 74 -j^is finding also helps 
assure the effectiveness of capsaicin in producing pharma¬ 
cological "sensory denervation," and therefore helps to 
rule out a sensory nerve component to vasopressin's actions 
on the pupil. 
Neurotensin, a recently isolated tridecapeptide with 
a widespread CNS distribution similar but not identical to 
that of enkephalin, has a broad spectrum of pharmacologic 
activities (hypothermia, hypotension, hyperglycemia, growth 
hormone and prolactin release); its presence in the eye 
(the amacrine cells of the pigeon retina) and its potent 
capillary permeability-increasing effects have made it an 
attractive candidate for mediator of ocular nociceptive 
79,86 
responses. This peptide, however, exerted only weak 

Page 58 
miotic effects on the isolated iris with a potency at least 
two orders of magnitude less than that of substance P or 
AVP. 
A number of indirect and direct mechanisms have been 
8 7 
ascribed to the pupillary effects of morphine; this 
multiplicity of mechanisms apparently accounts for the great 
interspecies variability of its effects on the pupil. Opiates 
cause prominent centrally-mediated miosis in man and dogs, 
but they cause mydriasis in cats by causing adrenal medullary 
88 
release of epinephrine. Recently, a child with subacute 
necrotizing encephalomyelopathy was reported to have re¬ 
markably elevated levels of endophins (especially enkephalins 
89 in the CSF and in the post-mortem brain. The child had 
suffered from neurological attacks which were reminiscent 
of morphine-overdose and which were often partially allev¬ 
iated by naloxone. A naloxone-reversible miosis was con¬ 
sistently noted during these attacks. This fascinating case 
suggests that endogenous opiates are involved in pupil regu- 
89a lation--at least in certain pathological states. The 
present study failed to detect any in vitro pupillary 
effects of m et-enkephalin, thus favoring a central media¬ 
tion of enkephalin-induced miosis. 
Suggestions for Future Experiments 
The present work highlights several approaches that 
can be used to study physiologic actions on IOP and the pupil 
, 
. 
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The wide range of structural analogs now available 
can be used to determine whether the neurohypophyseal 
hormones have significant physiologic effects on IOP. An 
optimal approach would combine the use of these analogs with 
some method to prevent the interference of endogenous vaso¬ 
pressin or oxytocin. Antagonists such as d(CH)(Me)-AVP 
would be useful in eliminating pressor or oxytocic com- 
59 ponents of this interference; investigation of the in 
vivo actions of these antagonists alone would determine 
whether endogenous pressor or oxytocic activity played a 
significant role in regulation of IOP. However, greater 
difficulty is encountered when trying to remove interfering 
influences of endogenous ADH activity, because at present 
there is no specific ADH antagonist available. Several 
approaches to handling this problem do seem feasible. 
Ethanol loading has already been used with some success' 
however, because ethanol possesses its own smooth muscle 
and metabolic effects, another agent may be desirable. 
Possible alternatives are phenytoin, which also inhibits 
3 
release of ADH , and somatostatin, which inhibits vaso¬ 
pressin-induced activation of adenylate-cyclase in toad 
90 bladder epithelium. 
Once a reliable method for removing interfering in¬ 
fluences of endogenous vasopressin activity has been es¬ 
tablished, structural analogs such as DDAVP can be used 
to characterize the receptor mediation of the IOP response 
51,53 
' 
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in an approach analogous to the one used here to character¬ 
ize the pupillary response. The pupil's response may even 
prove to be a useful indicator of pharmacologic delivery 
of peptides that have inherent pressor activity, and may 
be a useful guide as to whether vascular effects are being 
exerted. 
Preliminary experiments have also illustrated how 
capsaicin-induced desensitization of the in vitro isolated 
preparation can be successfully implemented to study sen¬ 
sory neurotransmitter mediation of pupillary responses. 
An advantage of this system is the ease with which the 
desensitization can be assessed by monitoring the loss of 
pupil responsiveness to capsaicin. Additional experiments 
are needed to confirm the efficacy of this technique in 
producing sensory nerve terminal depletion of neurotrans¬ 
mitters. This could be accomplished either by using a 
radioimmunoassay or ELISA technique to directly assay neuro 
transmitter release in the perfusate and neurotransmitter 
depletion in the iris, or by demonstrating effectiveness 
in eliminating in vitro responses to other known neurally- 
mediated agents, such as nitrogen mustard or formalde- 
hyde.91'92 
The system is also well-suited to study mechanisms of 
release of putative sensory neurotransmitters such as sub¬ 
stance P. Given a sufficiently sensitive neuropeptide 
iris 
- 
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assay, the continuous perfusion apparatus of the in vitro 
system makes it possible to correlate time course of neuro¬ 
transmitter release with pupil response. Direct demonstra¬ 
tion that nociceptive agents such as bradykinin or prosta- 
93 94 glandins ’ act by releasing peptides such as substance P 
would have broad implications for future pharmacologic 
approaches to analgesic and anti-inflammatory therapy. 
- 
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TABLE 1 
SPECIFIC ACTIVITIES OF NEUROHYPOPHYSEAL PEPTIDES USED 
Peptide Rat Anti- 
diuresis 
(units/mg) 
Rabbit Milk 
Ejection 
(units/mg) 
Rat Pressor 
(units/mg) 
Source 
AVP 350 70 350 supplier 
AVT 255 220 260 Berde and ^ 
Boissonnas 
LVP 100 22.5 100 supplier 
DDAVP 870-4000 3.2 11 Vavra, et. al^ 
OT 5 500 5 supplier 
[d(CH2)5Tyr(Me)AVP] 
1 2 
CH2-CC-Tyr(r. 
3 4 5 6 7 6 
e)-Phe'Gln- Asn- Cy -Pro* Arg 
9 
Gly - NHp 
ch2ch2 j 
c< > 
ch2ch2 j (a) 
s— 
l 
H—C—H 
I 
H—C—H 
I 
o=c- D-Aro 
1 -Deomino-S p-Arc; nine Vcsop'essin 
(desmopressin, c'DAVPj 
(b) 
aFrom M. Kruszynski, et aU. J. Med. Chem. 23: 1980, p.365. 
From R.M. Hays, in Goodman and Gilman's; The Pharmacological 
Basis of Therapeutics, 6th ed. (New York: Macmillan, 
1980), p. 917. 
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TABLE 2 
POSSIBLE MECHANISMS BY WHICH NEUROHYPOPHYSEAL PEPTIDES MAY 
INFLUENCE INTRAOCULAR PRESSURE 
Possible Sites of Action 
on IOP 
Possible Vasopressin 
Anesthesia Interactions 
Inflow Plasma osmolarity known to cause ADH 
release 
i 
Volume changes secondary 
to vascular effects 
Probably 
only 
Transient 
and 
Volumetric 
Ef f ects 
Ciliary arteriole perfusion 
pressure 
-local vasoconstriction 
arteriole 
metarteriole 
known to alter local 
vascular tone and 
reflexes®^ 
post-capillary 
venule 
-systemic pressor known to enhance pressor 
V. effect effect 
Ciliary epithelial 
transport or water 
permeability 
Outflow Facility 
Pupillary block? 
Episcleral venous pressure? 
Outflow 
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TABLE 3 
Effects of Intravitreal Administration of Neurohypophyseal 
Peptides on Intraocular Pressure in the Rabbit 
Peptide Dose <£MOP mmHg S.E.M. Number of Animals 
AVT 0. lug + 2 7.07 2 
1. Opg +5a 1 
LVP 0.2IU 
-4.^ 2.12 2 
0.1IU 0.0 5.66 2 
0.02IU 0.5 4.95 2 
OT 0.25IU -1.5 2.12 2 
0.5IU -1.5 4.95 2 
1.0IU 0.0 1.41 2 
2.5IU +4.5C 0.71 2 
DDAVP 1. Opg -0.6 1.19 7 
0. ljug -1.3 0.81 3 
0.Olpg -1.0 1.22 3 
AIOP is the maximal difference in IOP observed (right eye 
left eye) following intravitreal administration of peptide 
in the right eye and saline in the left eye. 
(a) noted at 5 hours; (b) noted at 2 hours; (c) noted 
at 2, 9, and 27 hours. 
* 
FIGURE 1 
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DISTRIBUTION OF THE NEUROHYPOPHYSEAL HORMONES AMONG VERTEBRATES 
MAMMALS 
A VP, AVT, LVP.OT 
HOLOCEPHALANS - 7 - 
AVT, OT 
4-Glutamine peptides 
AVT * Arginine-vasotocin 
AVP« Arginine-vasopressin 
OT * Oxytocin 
MT * Mesotocin 
VT « Volitocin 
LVP* Lysine-vasopressin 
4-Serine peptides* 
GT* Giumitocin 
IT * Isotocin 
4-Asparagine peptide** 
AT» Aspartocin 
Underlined principles have been chemically identified 
in species representing the indicated groups. 
TABLE 1. The known naturally occurring 
active neurohypophysial peptides 
Peptide 
Amino acid 
positions 
\ 5 
in 
L 
1 'tisupressur prptuh'S 
Argimne-sasopressin Phe Gin Arg 
L\ sine-vasopressin Phe Gin Lvs 
Arginine-vasotocin lie (.In Arg 
0\\tin in-likf 
()\\toe in lie Gin Leu 
Mesotocin He Gin He 
Isotocin He Ser He 
Glmnitoc in He .Set Gin 
Aspartocin He Asn Leu 
Valilot in He Gin Val 
Common sinulure: 
i ———1 
From W.H. Sawyer. Federation 
Proc. 36: 1977, p.1843. 
C\S- r>r-\—V-Asrv('.vS-Pr«*-Z-Gly(NV,) 
I 234 5 6789 
. 
•- 
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FIGURE 2 
RESPONSES OF ISOLATED IRIS TO NEUROHYPOPHYSEAL PEPTIDES 
( ) refers to number of animals used for determination; unless 
otherwise indicated, N = 1. 
Responses to Substance P (SP) are included for comparison. 
■ 
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Figure 3 
Response of Isolated Iris to 60 Second 
Infusions of Oxytocin 
0.01 lU/ml 0.02 lU/ml 0.04 lU/ml 
Changes 0.16 mm 
in Diameter 
0.28 mm 0.52 mm 
TIME   —> 
Recorder output from spectrophotometer showing 
change in light absorbance in response to 60 
second infusions of oxytocin. Time scale is 
6 minutes per inch (2 minutes per division). 
Initial pupil diameter is 3.99 mm. 
. 
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FIGURE 4 
RESPONSE OF ISOLATED IRIS TO fCUROWtPOPKr'SEAL PEPTIDES 
C 
0 
N 
S 
T 
R 
I 
C 
T 
I 
0 
N 
X 
avp 
0 
avt 
A 
lvp □ 
ot 
A 
"Peptide concentrations used in 60 second infusions were 
converted to pressor units/liter and the results shown in 
Figure 2 replotted here accordingly. 
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FIGURE 5 
C 
0 
N 
5 
T 
R 
I 
C 
T 
I 
0 
N 
RESPONSE OF ISOLATED IRIS TO hELROHYPOPWl'SEAL PEPTIDES 
LOG CONCENTRATION (60 tec. infusions) in OXYTOCIC UNITS/L 
0 
av/t 
A 
Ivp □ 
ot 
A 
Peptide concentrations used in 60 second infusions were 
converted to oxytocic units/liter and the results shown 
in Figure 2 replotted accordingly. 
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FIGURE 6 
LINEWEAVER-BURK ANALYSIS OF VASOPRESSOR-INDUCED 
CONSTRICTION OF ISOLATED IRIS PREPARATION 
The relationship between pupillary constriction (V) and 
dose (S) in pressor units (see Figure 4) is expressed in 
the form of the Lineweaver-Burk. equation: t;=K {7; ) (-p) + 7; 
V m V S -V 
max max. 
'V ** was arbitrarily assigned at 90% constriction, and the 
max J ^ 
equation converted to the form: V /V - 1 = K (1/S). This 
max m 
equation was fitted by linear regression to a line 
through the origin (dotted line). The slope of the line 
qives the best fitted value for "K ." 3 m 
. 
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FIGURE 7 
TACHYPHYLAXIS OF RESPONSE TO BRADYKININ IN ISOLATED IRIS 
PREPARATION 
DOSE 
Each line represents the results obtained from a 
separate preparation. 
* indicates that Tween-20 was included in the buffer. 
■ 
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FIGURE 8 
MIOSIS RESULTING FROM INTRAVITREAL INJECTION OF VASOPRESSIN 
PEPTIDES 
DOSE (ng) 
( ) refers to number of animals; n=2 unless otherwise specified. 
Responses to substance P (SP) are included for comparison. 
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FIGURE 9 
TIME COURSE OF MIOSIS FOLLOWING INTRAVITREAL INJECTIONS OF LVP 
r 
04* □ 
-2 
-3 
-4 
-5 
- A □ A 
m a 
□ 
A 
□ 
• • 
A • 
• • A 
I 
CD 
□ 
□A 
□ 
A 
CA 
□ 
• 0.2 units LVP 
A 0.1 units LVP 
□ 0.02 units LVP 
JL 
13 5 10 15 20 
HOURS POST INTRAVITREAL INJECTION 
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The graph demonstrates that the larger doses of LVP 
produced an earlier onset of miosis. 
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FIGURE 10 
IN VIVO MIOSIS AND PRESSOR ACTIVITY 
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FIGURE 11 
IN VIVO MIOSIS AND ADH ACTIVITY 
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